The future of biologic agents in the treatment of Sjögren's syndrome.
Clin Rev Allergy Immunol
; 32(3): 292-7, 2007 Jun.
Article
em En
| MEDLINE
| ID: mdl-17992596
ABSTRACT
The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjögren's syndrome (SS) and the current availability of various biological agents (anti-TNF-alpha, IFN- alpha, anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention. In SS, various phase I and II studies have been performed to evaluate these new strategies. Currently, B cell-directed therapies seem to be more promising than T cell-related therapies. However, large, randomized, placebo-controlled clinical trials are needed to confirm the promising results of these early studies. When performing these trials, special attention has to be paid to prevent the occasional occurrence of the severe side effects.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Terapia Biológica
/
Fatores Biológicos
/
Síndrome de Sjogren
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article